Mathew Garnett

YouTube video by CRUK Manchester Institute Group Leader Recruitment at the Cancer Research UK Manchester Institute

Exciting news - we are recruiting new Group Leaders! 🥼

We are seeking to appoint exceptional early-career scientists & clinician scientists as #GroupLeaders to develop bold, innovative, high-impact #CancerResearch programmes

Full details on our website: www.cruk.manchester.ac.uk/career/new-g...

KRAS dependency in cell lines

DepMap Miner features:
· Tailor model data selections
· Explore relationships between 'omics' data
· customisable plots
· Visualise gene dependencies across 900+ cell lines
· Export data easily to continue exploring
Discover more: dataminer.depmap.sanger.ac.uk

depmap miner logo

The Garnett Lab is excited to launch DepMap Miner, a new tool to explore cancer dependency data!
Built on the Sanger DepMap, the DepMap Miner brings together multi-omic and functional datasets for over 1300 cancer cell models.

Start mining data now: dataminer.depmap.sanger.ac.uk

Exciting FULL PROFESSORSHIP at the Vienna BioCenter - Molecular Mechanisms of Disease Mechanisms: www.maxperutzlabs.ac.at/news/open-po... Come be our colleague!

Excited to be on my was to the GRC synthetic lethal approaches in oncology conference #GRCSyntheticLethal. Some stellar science kicking off tonight. In the meantime enjoying the beautiful scenery on the drive up the Maine coast.

Group Leader at the Wellcome Sanger Institute, David Adams stands outdoors, discussing the significant genetic discovery related to uveal melanoma and cancer therapy. His quote reads: “Our study reveals a previously unrecognised genetic relationship in uveal melanoma, driven by a particular relationship between the CDS1 and CDS2 genes. This discovery not only deepens our understanding of tumour biology but also opens new routes for precise therapy development. What makes this finding especially exciting is its relevance beyond uveal melanoma as our research suggests a therapeutic potential for a broad range of cancers.”

A new drug target that has the potential to treat aggressive eye cancer has been discovered 👁️

This research may provide a hopeful outlook for eye cancer patients with very limited treatment options and has implications for a range of other cancers ⤵️

www.sanger.ac.uk/news_item/ne...

Join the Frontier of Cellular Genomics at Wellcome Sanger Institute. We are looking for Group Leaders to drive innovative science with core funding, cutting-edge technology, and global impact.

Apply now: lnkd.in/eqneJFVt

📅 Closing date: 17 August

#GroupLeader #FacultyPosition #CambridgeScience

Now online in Cancer Discovery: AAnet Resolves a Continuum of Spatially-Localized Cell States to Unveil Intratumoral Heterogeneity - by Aarthi Venkat, Scott Youlten, Beatriz San Juan, Smita Krishnaswamy, Christine Chaffer, and colleagues doi.org/10.1158/2159...

Cancer Plasticity Atlas To Improve Cancer Therapies

Cancer Plasticity Atlas To Improve Cancer Therapies

#HelmholtzMunich joins @sangerinstitute.bsky.social & @parse.bsky.social to build the Cancer Plasticity Atlas, using #AI & single-cell data to model therapy response.

👉 t1p.de/13ifi

@fabiantheis.bsky.social
@mgarnett.bsky.social

#CancerResearch

Pioneering cancer plasticity atlas will help predict response to cancer therapies Utilising novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research.

Announcing a new collaboration with @parse.bsky.social @www.helmholtz-munich.de to develop a #Cancer Plasticity Atlas.

The reference map will help predict the effect of cancer drugs - where resistance might develop and where to target future treatment efforts.

www.sanger.ac.uk/news_item/pi...

This is going to be a great event showcasing cutting edge science.

Don't miss your chance to register for the GRC conference on Synthetic Lethality Approaches in Oncology this July in beautiful Maine (near Boston). We have stellar speakers, with a mix from academia and industry in this translational space. There are speaker slots from abstracts.

MLOmics: Cancer Multi-Omics Database for Machine Learning - Scientific Data Scientific Data - MLOmics: Cancer Multi-Omics Database for Machine Learning

MLOmics: Cancer Multi-Omics Database for Machine Learning 🧪 🧬🖥️ www.nature.com/articles/s41...

For students & trainees, there are speaking slots for selected abstracts at the upcoming GRC conference on Synthetic Lethality in Oncology (www.grc.org/synthetic-le...). The informal small meeting format is perfect for networking and to find your next career opportunity. Bursaries available.

Check out the first session for the upcoming GRC conference on synthetic lethality in oncology www.grc.org/synthetic-le.... Top flight speakers - Simon Powell (MSK), Chris Lord (ICR), and plenary talk from William Sellers (Broad Inst.). What a start! It's not too late to register.

Check this out if you're interested in #crispr #baseeditor. Congratulations Cansu for creating this wonderful tool.

Today, the ERC formally adopted a decision to increase its support for researchers moving to Europe.

On top of its normal grants, the ERC offers 'start-up' funding to help PIs establish laboratories / research teams in Europe.

This extra funding is now x2 (up to €2 million!)

europa.eu/!6Vdgmp

Learn about the future of synthetic lethality in oncology at the upcoming Gordon Research Conference. This is the inaugural meeting and WOW what a lineup! We have a truly phenomenal program, with top speakers from academia and industry. Check it out at the link below.
www.grc.org/synthetic-le....

A graphic for the Marie Skłodowska-Curie Actions (MSCA), showing a historical portrait of Marie Skłodowska-Curie overlaid with an image of four young researchers walking down a hallway. The European Commission logo is in the top left. Text reads: "Marie Skłodowska-Curie Actions – €404.3 million to support postdoctoral researchers”

Choose Science. Choose Europe.

A new Marie Skłodowska-Curie Actions Postdoctoral Fellowships 2025 call is now open.

With a budget of €404.3 million, it will support around 1,650 researchers from Europe and beyond.

Apply by 10 September → europa.eu/!fBTMgF

My dept in London at Imperial (Bioengineering) is recruiting a group leader at Professor level 🧑‍🎓 Please RT. It's a great place with world-class expertise in all sorts of biomedical & biological engineering topics like synthetic biology. It's also not in the USA. www.imperial.ac.uk/jobs/search-...

Great talk by Yanhua Rao at #AACR2025 on GSK’s new clinical WRN inhibitor. Proud to see our unpublished data spotlighted for revealing new MoA insights. Exciting times ahead! @mgarnett.bsky.social

Six years after the discovery of WRN synthetic lethality in MSI cancers, WRN inhibitors hit center stage again today at #aacr25 with report of the first in human phase 1 trial data for RO7589831. Can’t wait to see it!

I am speaking at #AACR25 this afternoon on our latest work on somatic mutations in normal tissues. If you are attending AACR, feel free to drop by and say hello.
brnw.ch/21wRUZZ

Just landed in Chicago for #AACR25 — Millennium Park in bloom! Excited for team talks on WRN inhibitors in MSI cancers, with first-in-human data discussed by @mgarnett.bsky.social at the Clinical Trials Plenary. I’ll present new data on WRNi-driven evolution — Poster #420! #MSI #SyntheticLethality

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...

Excited to announce our preprint today @biorxivpreprint.bsky.social
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...

The transcriptomic architecture of common cancers reflects synthetic lethal interactions - Nature Genetics Tumor cells upregulate compensatory buffering genes following tumor suppressor loss. These genes may represent new synthetic lethal partners that could be harnessed therapeutically.

Uncovering synthetic lethal vulnerabilities across cancers. Upregulation of #TWIST1/2, #VIM, and integrin components ( #ITGB5, #ITGAV, #FERMT2 ) constitutes a synthetic lethal buffering mechanism that preserves tumor fitness despite #CDH1 #Ecadherin loss #lobular #DGC
www.nature.com/articles/s41...

CellFlow enables generative single-cell phenotype modeling with flow matching High-content phenotypic screens provide a powerful strategy for studying biological systems, but the scale of possible perturbations and cell states makes exhaustive experiments unfeasible. Computatio...

Yay, we built a thing! With @dominik1klein.bsky.social Daniil, Aviv Regev, Barbara Treutlein @graycamplab.bsky.social @fabiantheis.bsky.social we use flow matching to enable generalised sc phenotype modeling. From cytokine screens to fate programming and organoid engineering tinyurl.com/3xhju7db

this week 20 years ago, Nature published two seminal papers showing for the first time that BRCA-mutant cells were selectively sensitive to PARP inhibitors, paving the way for clinical trials and approval of PARP inhibitors for patients with BRCA-mutant ovarian and breast cancers, and beyond.

How accurate are 'gene regulatory networks' inferred from scRNA-seq data?

This comprehensive analysis in @naturemethods.bsky.social concludes:
1. The areas under the precision-recall curve are moderate
2. Methods not using pseudotime-ordered cells are more accurate

HHMI Investigator David R. Liu, smiling, with a graphic of a DNA helix in the background. Text overlay announces his award of the 2025 Breakthrough Prize in Life Sciences.

Congrats to HHMI Investigator David R. Liu on receiving the 2025 Breakthrough Prize in Life Sciences! He is recognized for developing base editing & prime editing: 2 breakthrough gene-editing technologies that enable the correction or replacement of virtually any genetic mutation. hhmi.news/3RA6shj